Terns Shareholders Bet Merck’s $53 Takeout Is Too Low—Arbitrage Risks Rival Bids or Collapse

Merck has launched a definitive cash tender offer to acquire Terns Pharmaceuticals at $53.00 per share. This creates a near-term, binary arbitrage opportunity for investors. The deal's equity value is about $6.7 billion, which translates to a net acquisition cost of roughly $5.7 billion after accounting for Terns' cash. The offer price represents a 6% premium to Tuesday's closing price on March 24, the day before the deal was announced.

The immediate market setup is clear. As of the close on April 6, Terns shares were trading at $52.78, just below the $53 offer price. This pricing gap indicates the market is actively discounting the risk of deal failure. The primary execution risk is the shareholder approval requirement: the tender offer is only binding if more than 50% of Terns' outstanding shares are tendered. The current share price suggests investors are skeptical that the company can achieve that threshold, or that other closing conditions-like antitrust clearance-might falter.

The bottom line is a classic event-driven trade. The $53 offer price is fixed, but the path to closing is uncertain. The market is paying just under $53 today, effectively betting that the deal will not close. For an arbitrageur, the risk/reward is defined by that gap and the binary outcome: either the deal closes at $53, or it fails and the stock reverts to a lower value.

The Strategic Rationale: Why Merck is Paying This Price

Merck's stated reason for the deal is clear and urgent: to bolster its hematology portfolio ahead of a major patent cliff. The company is buying Terns to acquire its lead drug, TERN-701, a targeted oral therapy for chronic myeloid leukemia. This move is a direct play to fill a pipeline gap before Keytruda's patent expires in two years. The drug's early clinical data, which showed a majority of patients with resistant disease achieving a major molecular response, has been so compelling that it has already reshaped expectations for CML treatment.

Yet the price Merck is paying raises immediate questions. The 6% premium to Tuesday's close is among the lowest paid for a publicly traded drugmaker since at least 2018. That low multiple, analysts argue, vastly underestimates TERN-701's potential. Leerink Partners analyst Andrew Berens stated, "In our assessment, this deal price vastly underestimates the potential for TERN-701". His analysis suggests a "reasonable multiple" for a rival buyer would be 1.5 to two times peak sales, which would represent a meaningful premium to Merck's offer. This valuation gap is the core of the arbitrage thesis.

The low premium also creates a tangible catalyst for a competing bid. The deal's structure-a tender offer requiring a majority of shares-leaves the door open for rival pharmaceutical giants like AbbVie or Bristol Myers Squibb to step in. The market's skepticism, reflected in the stock trading below the offer price, may stem from this very possibility. As the evidence notes, investors dissatisfied with the deal terms could refuse to tender if they believe a higher bid is imminent. The 6% discount to the offer price is the market's bet that this competition will materialize.

The bottom line is a trade-off between timing and valuation. Merck is paying a low premium to secure a promising asset before its patent expiry, but it is doing so at a price that many analysts believe is too low. This sets up a binary outcome for the arbitrage: either the deal closes at $53, or a rival bidder emerges to force a higher price, potentially invalidating the current offer. The strategic rationale is sound, but the price paid makes the deal a high-stakes gamble on whether Merck can close the deal before a better offer appears.

Catalysts, Risks, and What to Watch

The path to closing this deal is defined by a clear sequence of events and mounting risks. The primary catalyst is the successful completion of the tender offer in the second quarter of 2026, which is contingent on shareholder approval. The deal is only binding if more than 50% of Terns' outstanding shares are tendered. The current share price, trading just below the $53 offer, suggests the market is betting that this threshold will not be met.

The key risks to the arbitrage thesis are threefold. First, there is a tangible risk of a shareholder revolt. The 6% premium is widely seen as low, and dissatisfied investors may refuse to tender if they believe a higher bid is imminent. Second, regulatory delays for TERN-701 itself could create uncertainty, though the drug is still in early development. Third, and most immediate, is the potential for rival bidders to emerge before the offer's expiration. The tender offer structure leaves the door open for competing pharmaceutical giants, and the market's skepticism is partly priced in that possibility.

What to watch is straightforward. The first signal will be the Terns board's recommendation, which has already been filed. A strong, unified board endorsement is critical to encouraging shareholders to tender. More importantly, watch for any competing bids announced before the offer expires on May 4, 2026. The entire arbitrage setup hinges on Merck closing the deal at $53. Any competing offer would force a higher price and invalidate the current trade. For now, the market is pricing in a failure, but the catalyst is the deal's successful execution.